628.71
  Price0.77%   +4.81
(After Hours: 627.71 -1.00 -0.16%)
Aug-12-22 06:50AM 2 Top Biotech Stocks to Buy Right NowThe Motley Fool
Aug-10-22 10:57AM Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in FocusZacks Investment Research
Aug-07-22 01:25AM Teva Pharmaceutical: A Gem Among Generic Pharmaceutical CompaniesSeeking Alpha
Aug-06-22 09:30AM If You Invested $10,000 in Regeneron Pharmaceuticals 5 Years Ago, This Is How Much You Would Have TodayThe Motley Fool
Aug-04-22 01:43AM Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues BeatZacks Investment Research
12:39PM Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2Zacks Investment Research
Aug-04-22 08:31AM Company News for Aug 4, 2022Zacks Investment Research
Aug-03-22 10:53AM Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, DupixentZacks Investment Research
10:24AM U.S. Stock Futures Rise on Strong Q2 EarningsZacks Investment Research
Aug-03-22 09:44AM Pre-markets Green on Strong Earnings NumbersZacks Investment Research
07:55AM Regeneron (REGN) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research
Jun-16-22 10:53AM Is Regeneron Absurdly Cheap or Has it Become a Value Trap?The Motley Fool
Jun-07-22 03:25AM Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One YearZacks Investment Research
Jun-06-22 11:12AM Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022Benzinga
Jun-04-22 07:50AM Wall Street Breakfast: What Moved MarketsSeeking Alpha
Jun-03-22 03:42AM Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock DownZacks Investment Research
11:31AM Regeneron (REGN) Down 1.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research
Jun-02-22 06:30AM Why Regeneron Wasn't a Healthy Stock TodayThe Motley Fool
04:15AM Markets Rise Amid Strength In Tech, SoftwareBenzinga
Jun-01-22 02:39AM Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIBZacks Investment Research
May-31-22 02:24AM 7 Analysts Have This to Say About Regeneron PharmaceuticalsBenzinga
10:16AM Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority TagZacks Investment Research
May-26-22 07:42AM Why Regeneron Investors Shouldn't Fear Its Patent CliffThe Motley Fool
May-25-22 12:05PM SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting GoalZacks Investment Research
10:06AM Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers UpdatesZacks Investment Research
May-25-22 01:09AM Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)Zacks Investment Research
May-23-22 12:26PM Regeneron's (REGN) Evkeeza Positive in Late-Stage StudyZacks Investment Research
10:33AM Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022Benzinga
May-23-22 10:20AM Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th IndicationZacks Investment Research
May-18-22 12:51PM The Correction In Biopharmaceutical Stocks Is Likely OverSeeking Alpha
May-13-22 08:42AM The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven PharmaceuticalZacks Investment Research
May-12-22 09:11AM Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory NewsZacks Investment Research
09:05AM Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?The Motley Fool
May-11-22 12:38PM Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in FocusZacks Investment Research
May-10-22 10:56AM Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1Zacks Investment Research
06:20AM Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?Zacks Investment Research
May-06-22 03:02AM Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues BeatZacks Investment Research
11:37AM Ultragenyx's (RARE) Q1 Earnings & Revenues Miss EstimatesZacks Investment Research
May-04-22 11:54AM Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales AffectedZacks Investment Research
07:45AM Regeneron (REGN) Q1 Earnings and Revenues Beat EstimatesZacks Investment Research
May-04-22 06:20AM Should You Invest in the iShares Biotechnology ETF (IBB)?Zacks Investment Research
May-02-22 06:22AM The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and BiogenZacks Investment Research
06:20AM Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?Zacks Investment Research
Apr-29-22 12:33PM Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue ViewZacks Investment Research
Apr-28-22 10:52AM Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales RiseZacks Investment Research
09:00AM Can a decades-old antidepressant keep COVID-19 patients out of the hospital?MarketWatch
Apr-28-22 06:20AM Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?Zacks Investment Research
Apr-27-22 03:03AM Regeneron (REGN) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research
07:11AM Can a decades-old antidepressant keep COVID-19 patients out of the hospital?MarketWatch
Apr-26-22 07:14AM Can a decades-old antidepressant keep COVID-19 patients out of the hospital?MarketWatch
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Cap:    |  Volume (24h):